名稱 | PVRIG(CD112R) Effector Reporter Cell |
型號(hào) | CBP74120 |
報(bào)價(jià) | ![]() |
特點(diǎn) | PVRIG(CD112R) Effector Reporter Cell,凍存條件:90% FBS+10% DMSO; |
產(chǎn)品搜索
相關(guān)文章
- 喝熱茶或使食管癌風(fēng)險(xiǎn)增加5倍
- 證據(jù):鍛煉或許并不是控制體重的關(guān)鍵
- 關(guān)于sigma試劑的使用時(shí)長(zhǎng)相關(guān)說(shuō)明
- 肺癌靶向治療:腫瘤不進(jìn)展時(shí)間超2年
- 一箭雙雕——IL-4R靶點(diǎn)和IL-4/IL-13雙重阻斷藥篩細(xì)胞模型
- IL36靶點(diǎn)藥物細(xì)胞篩選模型藥
- 腫瘤細(xì)胞培養(yǎng)實(shí)驗(yàn)的主要用途
- CCR8 | 潛在重磅腫瘤免疫治療靶點(diǎn)
- TIGIT&PVRIG雙靶點(diǎn)細(xì)胞篩選模型
- 重磅!科學(xué)家成功利用免疫細(xì)胞運(yùn)輸抗癌藥物至腫瘤靶點(diǎn)
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74120PVRIG(CD112R) Effector Reporter Cell

- 詳細(xì)內(nèi)容
I. Background | |
PVRIG(CD112R),是脊髓灰質(zhì)炎病毒受體(PVR)家族的共抑制受體,在自然殺傷細(xì) 胞(NK)和 T 細(xì)胞上表達(dá)。它與其配體(CD112 或 PVRL2/nectin-2)結(jié)合,抑制 T 細(xì)胞和 NK 細(xì)胞對(duì)癌癥的反應(yīng)。因此,CD112R 作為一種新的免疫檢查點(diǎn)抑制劑在癌癥治療中具有很高的潛力。 | |
II. Description | |
PVRIG(CD112R) Effector Reporter Cell 報(bào)告基因藥靶模型很好的模擬了體內(nèi) PVRIG 的 信號(hào)轉(zhuǎn)導(dǎo)過(guò)程,原理見(jiàn)下圖所示。 ![]() Figure 1. PVRIG(CD112R) Effector Reporter Cell | |
III. Introduction | |
Expressed gene: | PVRIG(CD112R) |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Synonym(s): | Poliovirus Receptor-related Immunoglobulin Domain-containing Protein, Transmembrane Protein PVRIG, 79270-1, 79270-2 |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+800μg/ml hygromycin+1μg/ml puromycin |
Mycoplasma Testing: | Negative |
Storage: | Liquid nitrogen |
Application(s): | Functional(Report Gene) Assay |
IV. Representative Data | |
Figure 2. Recombinant PVRIG(CD112R) Effector Reporter Cell stably expressing PVRIG(CD112R). | |
Figure 3. Dose Response of PVRIG Blocking Antibody in PVRIG(CD112R) Effector Reporter Cell (C7) With CD112 TCR Activator CHO (C1) |